240 related articles for article (PubMed ID: 11196151)
1. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Wang Y; Liu J; Wu Y; Luo W; Lin SH; Lin H; Hawk N; Sun T; Guo JQ; Estrov Z; Talpaz M; Champlin R; Arlinghaus RB
Cancer Res; 2001 Jan; 61(1):138-44. PubMed ID: 11196151
[TBL] [Abstract][Full Text] [Related]
2. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
Lin F; Monaco G; Sun T; Liu J; Lin H; Stephens C; Belmont J; Arlinghaus RB
Oncogene; 2001 Apr; 20(15):1873-81. PubMed ID: 11313935
[TBL] [Abstract][Full Text] [Related]
3. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
4. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
[TBL] [Abstract][Full Text] [Related]
5. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
6. Exon-skipping in BCR/ABL is induced by ABL exon 2.
Lichty BD; Kamel-Reid S
Biochem J; 2000 May; 348 Pt 1(Pt 1):63-9. PubMed ID: 10794714
[TBL] [Abstract][Full Text] [Related]
7. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA
Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728
[TBL] [Abstract][Full Text] [Related]
10. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
14. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB
Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
16. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
17. P210 BCR-ABL is complexed to P160 BCR and ph-P53 proteins in K562 cells.
Campbell ML; Li W; Arlinghaus RB
Oncogene; 1990 May; 5(5):773-6. PubMed ID: 2140598
[TBL] [Abstract][Full Text] [Related]
18. The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.
Lionberger JM; Smithgall TE
Cancer Res; 2000 Feb; 60(4):1097-103. PubMed ID: 10706130
[TBL] [Abstract][Full Text] [Related]
19. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Chu S; Li L; Singh H; Bhatia R
Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
[TBL] [Abstract][Full Text] [Related]
20. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
